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Abstract 
  
Objective: With an unacceptably low 5-year survival rate and few identified modifiable factors 
that affect head and neck cancer (HNC) outcomes, HNC survival remains an important public 
health problem. Vitamin D has been shown to be associated with immune reactivity and 
improved outcomes for some cancer sites, but findings are mixed and few studies have 
examined vitamin D in relation to HNC. This study aims to assess the association between 
vitamin D intake and survival outcomes in HNC patients. 
 
Methods: This prospective cohort study utilized data on 434 HNC patients with valid pre-
treatment food frequency questionnaire data who participated in the University of Michigan 
Head and Neck Specialized Program of Research Excellence (SPORE) epidemiology project.  
Cox proportional hazard models were used to estimate the associations between total, dietary, 
and supplemental vitamin D intake and HNC outcomes, while adjusting for other known 
prognostic factors. 
 
Results: After multivariable adjustment, we found a statistically significant inverse trend 
between total vitamin D intake and recurrence (Q4 vs Q1 HR=0.47, 95% CI=0.20 - 1.10, p-
trend=0.048). We observed no association with dietary or supplemental intake, separately, and 
no association was observed with all-cause or HNC-specific mortality. 
 
Conclusion: These findings suggest that HNC patients with lower levels of vitamin D intake 
are at higher risk of recurrence. If borne out in future studies, our results suggest that increased 
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vitamin D intake through dietary intervention or the use of supplements may be a feasible 
intervention for prevention of recurrence in HNC patients. 
Keywords: vitamin D, head and neck cancer, recurrence, survival  
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Introduction 
 
Head and neck cancer (HNC) accounts for approximately 3% of all new cancer cases 
each year in the United States (U.S.) Compared to 25 years ago, incidence has decreased but 
has remained relatively stable at approximately 11 per 100,000 men and women per year since 
2003. HNC is an important public health problem as it has unacceptably low rates of survival; 
the current 5-year survival rate for HNC is 64%. While smoking history has been shown to be 
associated with HNC clinical outcomes1, few other factors have been identified and, currently, 
there are no evidence-based recommendations for prevention of recurrence and death after 
treatment. 
Vitamin D is well known for the beneficial role it plays in bone metabolism, calcium 
absorption, and immune function.2,3 Using National Health and Nutrition Examination Survey 
data from 2005-2006, Forrest et. al found an overall vitamin D deficiency prevalence of 45% in 
the United States (U.S.).4 Vitamin D deficiency is hypothesized to be associated with a number 
of negative health outcomes, including diabetes, cardiovascular disease, and cancer.5,6 
Laboratory studies have established several biologic actions of vitamin D that may play a critical 
role in cancer incidence and mortality. It is thought that vitamin D acts through the vitamin D 
receptor (VDR) to produce its anti-carcinogenic effects and potentially regulate immune cells.2 
This known transcription factor is responsive to binding of vitamin D, is expressed in many 
normal and malignant tissues, binds target genes that regulate cellular growth and have shown 
to be deleted or down-regulated in tumor tissue.7 Pre-clinical studies of the biologically active 
form of vitamin D, 1,25(OH)2D, also support vitamin D-mediated anti-proliferation and induced 
apoptosis of cancerous cells.5 
 
However, epidemiologic studies have produced mixed evidence of the role of vitamin D 
in risk of cancer. 8 Higher circulating vitamin D levels have been found to lower the risk of 
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colorectal cancer.8,9 Few studies, however, have examined vitamin D in relation to risk of HNC. 
A prospective cohort study in Helsinki, Finland determined that at the time of diagnosis, vitamin 
D insufficiency was significantly more prevalent in HNC patients compared to the Finnish 
general population.10 Furthermore, polymorphisms in the VDR gene have shown to influence 
risk of HNC, dependent on genotype.11 Despite our growing knowledge of the effect of vitamin D 
on cancer risk, relatively little is known about the role vitamin D status has in cancer survival. A 
few studies have suggested a protective role of vitamin D on survival in cancers of the prostate, 
colorectum, and breast.12,13,14 However, the relationship between vitamin D status and survival 
in HNC has particularly not been well characterized. A recent study found significantly increased 
survival for HNC patients with higher circulating vitamin D but further research is needed to 
confirm these findings.15 
 
Our aim in this study is to assess the association of pretreatment dietary and 
supplemental vitamin D intake on survival in HNC patients.  We leveraged previously collected 
food frequency questionnaire and survival and recurrence data on 434 newly diagnosed HNC 
patients recruited through the Head and Neck Cancer Specialized Program of Research 
Excellence (SPORE) at the University of Michigan Health System. Given the high prevalence of 
vitamin D deficiency, further understanding of this relationship is essential to informing clinicians 
of the potential therapeutic role of vitamin D in providing better outcomes for patients with HNC. 
 
 
 
Materials and Methods 
 
Study Population 
This was a prospective cohort study of 1031 newly diagnosed HNC patients recruited 
into the University of Michigan Head and Neck SPORE between 2008 and 2014. Patients were 
identified and recruited through the University of Michigan Health System with approval through 
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the Institutional Review Board at the University of Michigan Medical School. All enrolled 
participants gave signed, informed consent to their information being used in research studies. 
The dataset of 1031 HNC patients had previously excluded those that were less than 18 years 
of age, pregnant, non-English speaking, diagnosed with mental instability, or diagnosed with 
another primary cancer. We further excluded participants who had incomplete food frequency 
questionnaire (FFQ) information (n=449), those with implausibly high (calories/day > 5000, n=7) 
nutrient intake values, participants who were incorrectly diagnosed or dropped out of the study 
(n=16), or with missing survival time (n=8), and participants with rare cancer sites (i.e. “skull 
bone”, “nasopharynx” or “salivary gland”, n=15). Finally, participants consuming an abnormally 
low number of calories were excluded (calories/day <1200, n=102) in order to avoid reverse 
causation (i.e. that the symptoms of advanced disease would prevent patients from eating 
normally). Thus, our analytic cohort consisted of 434 participants. Recurrence analyses were 
further restricted to only participants without persistent disease (N=389). Further analyses 
included assessing the association between total vitamin D intake and HNC outcomes when 
stratifying by stage, sex, and BMI independently. 
 
Exposure  
Vitamin D intake data was calculated from validated semi-quantitative Harvard Food 
Frequency Questionnaires (FFQ) that were self-administered by the patients at the time of 
diagnosis.16 Our main exposure variable, total vitamin D intake, included both dietary and 
supplemental vitamin D intake and was categorized into quartiles (Q1 <200, 200≤Q2<465, 
465≤Q3<675, Q4≥675) for analysis. Dietary and supplemental vitamin D intake individually and 
duration of supplemental vitamin D intake were further analyzed as exposure variables.  
 
Covariates 
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After diagnosis, each participant was approached by a trained interviewer who 
completed an initial evaluation and provided participants with a self-administered questionnaire 
which included information demographic variables (age and sex), education level (Less than 
High School, High School Diploma, Some College, 4 years of College, More than College) and 
detailed information on history of tobacco (current, former, never) and alcohol use (current, 
former, never). Total caloric intake data was collected from the administered food frequency 
questionnaire at baseline. HPV status was assessed by either PCR technique or in-situ 
hybridization for patients with available tumor tissue (positive, negative, missing). Site 
(Laryngopharynx, Oral Cavity, Oropharynx, Unknown) and stage (Stage 1, 2, 3, and 4) data 
were collected during initial tumor evaluation at the time of diagnosis. Hypopharynx cases 
(n=11) were included with larynx cases in the laryngopharynx category. The baseline health 
questionnaire as well as medical record reviews were used to collect comorbidity data and 
scored using the Adult Comorbidity Evaluation-27 (ACE score 0, 1, 2, and 3).17 In many clinical 
studies of head and neck cancer, treatment is heterogeneous and the chosen treatment for any 
given disease site and stage may differ from physician to physician. However, at the University 
of Michigan, uniform treatment approaches are implemented across the patient population, 
within strata of disease site and stage, minimizing the potential for confounding by treatment 
effectiveness. All patients were evaluated by our multidisciplinary team and discussed at our 
tumor board where standardized treatment recommendations were made.1 
 
Outcomes 
Outcome variables included death from any cause (n=108), HNC-specific death (n=66), 
and recurrence of disease (n=99). Survival and recurrence times were measured from time of 
diagnosis to time of event. The mean survival time was 3.37 years (range: 0.11 - 7.16 years). 
The mean time to recurrence was 2.59 years (range 0.003 - 7 years). Follow-up to determine 
recurrent or persistent disease was conducted through patient visits, medical record reviews 
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and surveys according to the National Comprehensive Cancer Network guidelines.18 Death 
events were collected through annual medical record reviews, family notification, Lexis Nexis, 
and through the Social Security Death Index.  LexisNexis is a public record database which 
compiles information from various sources, including the Social Security Death Master File.  We 
utilized the database to obtain information on vital status for all SPORE subjects who were still 
considered to be alive at the time of the final survival update (April 2016). The database 
receives routine data updates from its various sources, so we conservatively estimated the 
information obtained was valid within six months of the time of the search. Censoring dates 
varied by participant and were designated as either their last medical record review date or 
Lexis Nexis search, ranging from April 15, 2016 to May 25, 2016. 
 
Statistical Analysis 
Descriptive statistics (mean(sd) for continuous variables, frequency (%) for categorical 
variables) were generated for all covariates with potential to be included in our final model. 
Covariate association with total vitamin D intake was assessed using chi-square association 
tests for categorical variables and t-tests for continuous variables. Our final model included 
adjustments for the following variables known or hypothesized to be associated with both the 
outcome and the exposure: age, site, stage at diagnosis, education level, HPV status, smoking 
status, drinking status, total calorie intake, and ACE score. Adjusting for these covariates, the 
association between vitamin D intake exposures and survival was assessed using cox 
proportional hazard models to generate hazard ratios (HR) and their corresponding 95% 
confidence intervals (CI). We examined the associations stratified by sex, BMI and stage at 
diagnosis. Statistical interaction was assessed using the likelihood ratio test. SAS 9.4 (SAS 
Institute Inc.) was used to perform all statistical analyses. 
 
 
Results 
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Characteristics of the study participants by quartiles of total vitamin D intake for the 
analyzed cohort can be found in Table 1. Most participant characteristics were similar across 
quartiles of vitamin D intake. However, compared to participants with lower vitamin D intake, 
those with higher intake were more likely to be older, consumed more calories, and were more 
educated (Table 1).  
 
We found no association between increasing levels of total vitamin D intake and all-
cause or HNC-specific mortality. However, we found a significant inverse trend across quartiles 
of vitamin D intake for recurrence (Q4 vs. Q1 HR=0.47, 95% CI=0.20 - 1.10; p-trend=0.048; 
Table 2). Upon stratifying by stage, the association between total vitamin D intake and survival 
time appeared similar in both those diagnosed at early and late stages but the inverse 
association between total vitamin D intake and recurrence appeared stronger in individuals with 
stage 4 disease (Supplemental Tables 1 and 2). When we examined dietary intake of vitamin D 
and supplemental intake separately, we found no association with both all-cause survival, HNC-
specific survival, or recurrence (Supplemental Tables 3 and 4). Upon stratifying by sex, a 
nonsignificant inverse association was found between total vitamin D intake and recurrence in 
men. In women, however, hazard ratios were uninterpretable due to small sample size 
(Supplemental Tables 4 and 5). We observed no interaction between BMI and total vitamin D 
intake (p-interaction=0.95).  
 
 
Discussion 
 
 In this prospective cohort study of HNC patients, although we found no association 
between vitamin D intake and all-cause or HNC-specific mortality we did observe a lower risk of 
recurrence with higher levels of total vitamin D intake. 
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To our knowledge, no previous studies have examined vitamin D intake in relation to 
HNC recurrence among HNC patients. However there have been two previous studies 
assessing the relationship between vitamin D and HNC survival, which have reported mixed 
findings.15,19 A study conducted by Meyer et al. found no association between combined dietary 
and supplemental vitamin D intake pre-treatment and overall mortality and recurrence in HNC 
cases.19  In contrast, a study by Fanidi et al. found low circulating vitamin D concentrations to be 
associated with a higher risk of all-cause deaths in HNC patients.15 It should be noted that 
Fanidi et al. measured circulating 25(OH)D levels while both the present analysis and the study 
by Meyer et al. examined vitamin D intake. Another distinction is that Fanidi et al. evaluated 
vitamin D status pre-diagnostically while both our study and that by Meyer et al. assessed 
vitamin D intake in HNC patients prior to treatment. Difference in timing of exposure assessment 
relative to diagnosis and the use of dietary intake vs. blood measurements may contribute to the 
differing results between these studies.  
 
Vitamin D has multiple biologic actions that are thought to contribute to its protective role 
in cancer incidence and progression including roles in regulating cell proliferation and 
differentiation, reducing invasion, being pro-apoptotic, and anti-angiogneic.20 One possible 
biologic mechanism of particular interest in head and neck cancer is the regulatory activity of 
vitamin D on immune cells within HNC tumors. Previous studies have demonstrated that the 
pattern of immune cell populations within tumors can be used as a prognostic factor to predict 
recurrence and survival. The effect of infiltrating immune cells on tumor progression varies by 
tumor histology, stage and microenvironment.21 In a previous study conducted in the University 
of Michigan Head and Neck SPORE, Nugyen et al. found that quantifying subsets of tumor 
infiltrating lymphocytes (TILs) could be used to predict HNSCC (Head and Neck Squamous Cell 
Carcinoma) outcomes. Specifically, patients with tumors that had higher levels of CD4 and CD8 
TILs individually showed increased overall survival but the effect of TIL level on survival differed 
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by HNSCC site.22 While the effect of vitamin D status on survival by TIL status has not been 
characterized in HNC, one study conducted in colorectal cancer patients reported that higher 
plasma 25(OH)D vitamin D status was associated with better survival , but only for tumors that 
had high levels of TILs.23 This suggests that the effects of vitamin D depend on tumor immune 
status and may partly explain the results we obtained from our study. The unknown immune 
statuses of tumors in our cohort along with our outcome comprising a group of unique tumor 
sites may explain the lack of the effect we observed of vitamin D on survival. Unfortunately, our 
analysis wa  underpowered to examine individual sites separately. Future studies are 
necessary to elucidate how vitamin D interacts with the tumor immune system to affect HNC 
tumor initiation and progression and whether its influence differs by tumor site. 
 
Although we observed an inverse association for HNC recurrence, we observed no 
association for overall or HNC-specific mortality. This lack of association may potentially be 
explained by differences in liver and kidney function. Vitamin D3 taken in through the diet is 
converted to 25(OH)D3 in the liver by vitamin d hydroxylases. This is the major form of 
circulating vitamin D which is then converted to the hormonally active form, 1,25(OH)2D, in the 
kidney.24 Thus, the health of an individual’s liver and kidneys can affect the bioavailability of 
ingested dietary and supplemental vitamin D.25 Individuals with a high intake of vitamin D may 
not experience the full effect if their liver and kidneys are not functioning properly, and liver and 
kidney impairment would be expected to be strongly associated with mortality, but not HNC 
recurrence. Although adjusting for ACE score did not alter our findings, it is possible that 
residual confounding by liver or kidney function could exist. Alternatively, if a protective 
association for vitamin D is specific to HNC, we might have expected to see protection for HNC 
recurrence and HNC-specific survival, but not overall survival. Despite the fact that we had a 
fairly large sample size of 434 patients with this rare cancer, we may have been underpowered 
to observe an association for HNC-specific mortality. Future studies in large populations of HNC 
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patients and randomized controlled trials are needed to establish whether vitamin D intake may 
improve HNC outcomes.    
 
Our study has some limitations including the lack of sunlight exposure data for our 
cohort. As sunlight exposure is known to increase blood vitamin D levels, measurement of 
vitamin D intake alone may not accurately reflect vitamin D status. However, because the 
exposure was assessed prospectively, any errors in vitamin D measurements due to missing 
sunlight exposure data are likely to be non-differential with respect to the outcomes of interest.  
Thus, this source of measurement error would have attenuated our results toward the null. 
Another limitation in our study design was the use of FFQ data which are self-reported and 
subject to inaccurate recall. However, a strength of using an FFQ is that it assesses usual 
vitamin D intake in the year prior to treatment while circulating levels are typically assessed at 
one time point. Therefore, using these vitamin D intake measurements may be more 
representative of vitamin D status over a longer period compared to a one-time serum level 
measurement. Finally, we had limited power to conduct stratified analyses by other potentially 
effect modifying factors such as sex, disease site, and HPV-status.26 
 
The strengths of our study include its prospective design and large sample size for a 
rare cancer type of 434 HNC cases. To our knowledge, this is the first prospective cohort study 
of HNC patients that has collected and analyzed FFQ data. Information was available for a 
number of potential confounders to be adjusted for in our final models. All patients in our cohort 
were evaluated and treated through the University of Michigan Health System, decreasing 
potential inconsistencies in clinical data reporting and differences in outcomes due to 
differences in treatment.  
In conclusion, in this large prospective cohort study of HNC patients, we found that 
higher vitamin D intake was associated with a lower risk of HNC recurrence. If borne out in 
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future studies, our results suggest that increased vitamin D intake through dietary intervention or 
the use of supplements may be a feasible intervention for prevention of recurrence in HNC 
patients. Further study is required to determine when in the natural history of HNC vitamin D 
may be most effective and if particular subgroups of HNC patients may be more likely to benefit 
from increased vitamin D intake.
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tTable 1: Cohort Characteristics by Quartiles of Vitamin D Intake   ____________________________________________________________________________ 
                                                        
 Total Vitamin D Intake Quartiles (IU/day) 
 
 
 <200           [200-465) [465-675) >=675 p-value 
N 108 108 109 109  
Age in years at 
Diagnosis (SD) 
 
58.6(12.7) 
 
58.5(11.1) 
 
60.0(9.5) 
 
63.1(10.4) 
 
.0014 
Sex 
    Male 
 
86(80.4%) 
 
86(80.4%) 
 
87(80.6%) 
 
80(73.4%) 
 
.493 
Smoker 
    Current 
    Former 
    Never 
 
44(40.7%) 
37(34.3%) 
27(25.0%) 
 
44(40.7%) 
38(35.2%) 
26(24.1%) 
 
37(33.9%) 
36(33.0%) 
36(33.0%) 
 
40(36.7%) 
45(41.3%) 
24(22.0%) 
 
 
 
.531 
Drinker 
    Current 
    Former 
    Never 
 
77(71.3%) 
26(24.1%) 
5(4.6%) 
 
79(73.2%) 
24(22.2%) 
5(4.6%) 
 
86(78.9%) 
19(17.4%) 
4(3.7%) 
 
69(63.3%) 
31(28.4%) 
9(8.3%) 
 
 
 
.288 
Cancer Site 
  Laryngopharynx 
  Oral Cavity 
  Oropharynx  
  Unknown 
 
23(21.3%) 
43(39.8%) 
38(35.2%) 
4(3.7%) 
 
29(26.9%) 
28(25.9%) 
42(38.9%) 
9(8.3%) 
 
21(19.3%) 
35(32.1%) 
46(42.2%) 
7(6.4%) 
 
24(22.0%) 
39(35.8%) 
42(38.5%) 
4(3.7%) 
 
 
 
 
.476 
Stage  
    1   
    2 
    3 
    4 
 
20(18.5%) 
12(11.1%) 
17(15.7%) 
59(54.6%) 
 
17(15.7%) 
13(12.0%) 
14(13.0%) 
64(59.3%) 
 
20(18.4%) 
11(10.1%) 
13(11.9%) 
65(59.6%) 
 
17(15.6%) 
12(11.0%) 
16(14.7%) 
64(58.7%) 
 
 
 
 
.996 
Ace Score 
    0(none) 
    1(mild) 
    2(moderate) 
    3(severe) 
 
30(27.8%) 
56(51.6%) 
19(17.6%) 
3(2.8%) 
 
31(29.0%) 
47(43.9%) 
19(17.8%) 
10(9.4%) 
 
33(30.3%) 
52(47.7%) 
17(15.6%) 
7(6.4%) 
 
24(22.0%) 
54(49.5%) 
22(20.2%) 
9(8.3%) 
 
 
 
 
.638 
HPV Status 
   Negative 
   Positive 
   Unknown 
 
38(35.2%) 
16(14.8%) 
54(50.0%) 
 
32(29.6%) 
23(21.3%) 
53(49.1%) 
 
30(27.8%) 
23(21.3%) 
55(50.9%) 
 
33(30.3%) 
19(17.4%) 
57(52.3%) 
 
 
 
.819 
BMI (kg/m
2
) 27.8 (5.9) 27.4 (6.0) 27.4 (5.8) 27.8 (5.6) 0.44 
Average Daily 
Calorie Intake 
(SD) 
 
 
1942(573) 
 
 
2232(701) 
 
 
2106(697) 
 
 
2324(738) 
 
 
<.0006 
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tAverage Hours 
Walked Per 
Week 
 
4.7(6.0) 
 
4.8(5.9) 
 
4.6(5.2) 
 
4.3(5.1) 
 
.620 
Average Hours 
Sitting Per Week 
16.6(8.9) 16.5(9.2) 16.7(9.0) 18.4(8.3) .166 
Average Hours of 
Light Exercise 
Per Week 
 
1.3(2.9) 
 
1.3(3.8) 
 
0.9(2.7) 
 
0.9(2.6) 
 
.275 
Average Hours of 
Moderate 
Exercise Per 
Week 
 
0.3(1.2) 
 
 
0.2(0.9) 
 
0.2(1.1) 
 
0.2(1.1) 
 
.754 
Average Hours of 
Strenuous 
Exercise Per 
Week 
 
0.4(2.8) 
 
 
0.6(2.9) 
 
0.7(2.1) 
 
0.6(1.8) 
 
.654 
 
Highest 
Education Level 
   More than Coll 
   4 year College 
   Some College 
   HS Diploma 
   Less than HS 
 
 
9(8.4%) 
12(11.2%) 
41(38.3%) 
36(33.6%) 
9(8.4%) 
 
 
17(16.0%) 
13(12.3%) 
39(36.8%) 
27(25.5%) 
10(9.4%) 
 
 
22(20.4%) 
13(12.0%) 
43(39.8%) 
24(22.2%) 
6(5.6%) 
 
 
23(21.1%) 
16(14.7%) 
36(33.0%) 
28(25.7%) 
6(5.5%) 
 
 
 
 
 
 
.007 
N=434 
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tTable 2: Cox Proportional Hazard Models of Total Vitamin D Intake Quartiles  
 
                             Total Vitamin D Intake(IU/day) 
<200                       [ 200-465)                          [465, 675)                    >=675 
p-value  
for trend 
HNC-specific 
Death 
     # Deaths 
17,592.14 p-mos 
   HR (95% CI)
 † 
   HR (95% CI)
 ‡ 
 
 
   18                        12                             15                        21 
4277.45               4623.77                     4533.09                4157.83 
1.0(ref)          0.60(0.29, 1.25)          0.73(0.37, 1.46)    1.01(0.54, 1.90) 
1.0(ref)          0.55(0.25, 1.20)          0.65(0.32, 1.35)    0.79(0.40, 1.56) 
 
 
 
 
.814 
.707 
Overall Death 
     # Deaths    
17,592.14 p-mos 
   HR (95% CI)
 † 
   HR (95% CI)
 ‡
 
 
   27                        24                             25                        32 
4277.45               4623.77                     4533.09                4157.83 
1.0(ref)          0.82(0.47, 1.42)          0.82(0.47, 1.41)    1.00(0.60, 1.67) 
1.0(ref)          0.71(0.39, 1.27)          0.73(0.41, 1.29)    0.84(0.48, 1.47) 
 
 
 
.967 
.656 
Recurrence 
     # Recurring 
13,115.27 p-mos 
   HR (95% CI)
 † 
   HR (95% CI)
 ‡
 
 
   14                       19                             16                          10 
3049.76              3509.75                    3443.55                  3112.21 
1.0(ref)          1.16(0.58, 2.32)        0.94(0.46, 1.93)      0.57(0.25, 1.28) 
1.0(ref)          1.19(0.57, 2.49)        0.90(0.42, 1.92)      0.47(0.20, 1.10) 
 
 
 
.139 
.048 
†:age-adjusted 
‡:adjusted for age, smoking status, alcohol status, hpv status, highest education level, ACE 
score, total calorie intake, disease site, and stage. 
N=434, Recurrence analysis N=389 
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